What Santisa does

Santisa Laboratório Farmacêutico S.A. is a privately held Brazilian pharmaceutical laboratory headquartered in Bauru, São Paulo, operating continuously since 1974 with 101–250 employees. The company manufactures and distributes 17 pharmaceutical products spanning four ANVISA regulatory categories — Genéricos (5), Similares (7), Específicos (3), and Notificados (2) — delivered as injectables, tablets, syrups, and sprays. Its strategic emphasis is on sterile injectable medications, supported by a dedicated R&D center established at the Bauru site in 2012 that covers pre-formulation, drug master file development, analytical and microbiological development, pharmaceutical technology, packaging, and technical documentation. Production runs in facilities validated under RDC 658/2022, IN 138/2022, PIC/S, GAMP 5, and EMA-aligned standards.

The business operates three revenue streams. The first is direct pharmaceutical product sales — generic, similar (brand-name generic), specific, and notified medications — distributed through a nationwide network of regional sales representatives (RCAs), an e-commerce storefront on santisa.com.br, and government procurement channels including PDPs and PDIL partnerships. The second is CMO/CDMO contract manufacturing and development services for other pharmaceutical firms seeking sterile injectable capacity, regulatory compliance, and validated process scale-up. The third is licensing in/out arrangements and strategic alliances pursued through a dedicated New Business area, including public health partnerships under the SUS framework. Customers split across three segments: Brazilian healthcare providers and patients (primary), other pharmaceutical companies on a B2B basis (secondary), and government and public health entities (vertical).

GTM motion combines direct-to-consumer distribution, a partner/channel motion through RCAs and government tenders, and a sales-led prospecting motion for CMO/CDMO and licensing deals. Marketing presence is concentrated on the corporate website, with supplementary LinkedIn activity, WhatsApp customer service (SAC), email marketing, and trade show participation (e.g., FCE Pharma). Pricing for retail-channel products is largely marked 'sob consulta' (upon consultation), with notified products surfaced in a R$0–R$40 range on the public catalog. The company is structured as a Brazilian Sociedade Anônima (CNPJ 04.099.395/0001-82) with no disclosed parent company, institutional investors, or funding rounds.

Name

Santisa

Legal name

Santisa Laboratório Farmacêutico S.A.

Website

https://santisa.com.br

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

101–250 employees

Short description

Santisa is a privately held Brazilian pharmaceutical laboratory in Bauru, São Paulo, manufacturing 17 generic, similar, specific, and notified injectable medications under ANVISA compliance, serving hospitals, pharmacies, government health programs, and B2B pharmaceutical clients through CMO/CDMO and licensing services.

Ownership category

akta.pro rank

Headquarters

HQ city

Bauru

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Genéricos, Similares, Específicos, Notificados): Santisa generates revenue primarily from the manufacture and sale of generic, similar (brand-name generic), specific, and notified pharmaceutical products. Products include injectables, tablets, syrups, and sprays distributed through sales representatives, pharmacies, hospitals, and government procurement channels across Brazil.
2. Contract Manufacturing & Development (CMO/CDMO): Santisa offers contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services to other pharmaceutical companies, providing production capacity, regulatory compliance, and development services for injectable product lines.
3. Licensing and Strategic Partnerships: The company pursues licensing in/out arrangements and strategic alliances with other pharmaceutical companies to expand its portfolio, access new products, technologies, and intellectual property, and enter new markets through Parcerias para o Desenvolvimento de Produtos (PDPs) and public health partnerships.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Santisa is a Brazilian pharmaceutical laboratory that manufactures and sells generic, similar (brand-name generic), specific, and notified medications—including injectables, tablets, syrups, and sprays—distributed through a nationwide network of sales representatives, pharmacies, hospitals, and e-commerce. It also offers contract manufacturing (CMO/CDMO) and R&D services to other pharmaceutical companies, with a strategic focus on injectable drug products and full ANVISA regulatory compliance.

Product overview

Santisa Laboratório Farmacêutico is a Brazilian pharmaceutical company with over 51 years of market presence, specializing in the development and production of injectable medications. The company's product portfolio comprises 17 pharmaceutical products organized across four regulatory categories: Genéricos (generic medications including esketamine hydrochloride, diazepam, dipyrone, and gentamicin sulfate), Similares (similar medications including diuretics Furosantisa and furosemida, antiemetic Metoclosantisa, benzodiazepines Santiazepam, and analgesic Santidor), Específicos (specific products including B-complex vitamin Santiplex B, lactulose laxative Lactosan, and vitamin C Vitasantisa C), and Notificados (notified medications including Paracetamol drops and nasal spray Rinosantisa). Beyond manufacturing its own branded products, Santisa offers contract manufacturing (CMO/CDMO) services for injectable product lines and comprehensive R&D services spanning pre-formulation, analytical development, microbiological development, pharmaceutical development, packaging development, and technical documentation. The company maintains a dedicated Research and Development center in Bauru focused on injectable medication development.

Differentiator

Problem solved

Functional benefit

Products and services

• Cloridrato de escetamina (Esketamine Hydrochloride) Generic injectable medication containing esketamine hydrochloride at 50 mg/mL concentration, presented as solution for injection in amber ampoules. For healthcare providers and patients requiring a generic anesthetic/analgesic injectable.
• Diazepam Injectable Generic injectable benzodiazepine medication at 5 mg/mL concentration for sedation and anxiety management. Targeted at hospitals and clinics.
• Dipirona Monoidratada (Metamizole) Injectable Generic analgesic and antipyretic medication (metamizole) in injectable form at 500 mg/mL concentration. For pain and fever management in healthcare settings.
• Sulfato de Gentamicina (Gentamicin Sulfate) Injectable Generic aminoglycoside antibiotic injectable medication available in 1mL and 2mL ampoule presentations for hospitals and clinics.
• Gentamisan (Gentamicin Similar) Similar aminoglycoside antibiotic injectable medication at 40 mg/mL concentration offered as a brand-name generic alternative to the reference product.
• Furosantisa (Furosemide Similar) Injectable Loop diuretic similar to reference product, presented as injectable solution at 10 mg/mL concentration for treatment of edema and hypertension-related conditions.
• Furosemida (Furosemide Generic) Generic loop diuretic injectable medication for treatment of edema and related cardiovascular conditions.
• Metoclosantisa (Metoclopramide Similar) Similar antiemetic and gastroprokinetic medication containing metoclopramide hydrochloride at 5 mg/mL for injectable use in clinical settings.
• Santiazepam Comprimidos (Diazepam Tablets) Similar benzodiazepine medication in tablet form, available in 5 mg and 10 mg doses, packaged in polyethylene sachets of 500 or 1000 units.
• Santiazepam Solução Injetável (Diazepam Injectable Solution) Similar benzodiazepine injectable solution containing diazepam in 2 mL amber ampoules for intravenous or intramuscular administration.
• Santidor (Dipyrone Similar) Similar analgesic and antipyretic medication containing dipyrone monohydrate for pain and fever management across consumer and healthcare-provider channels.
• Santropina (Atropine Similar) Similar anticholinergic medication containing atropine sulfate for pre-anesthetic sedation and bradycardia treatment in clinical settings.
• Santiplex B (Vitamin B Complex Injectable) Specific B-complex vitamin injection combining thiamine, riboflavin, pyridoxine, nicotinamide, and dexpanthenol for vitamin B supplementation in nutritional deficiency treatment.
• Lactosan (Lactulose Syrup) Specific lactulose syrup medication at 667 mg/mL concentration for treatment of constipation and hepatic encephalopathy, available in 120 mL bottles with plum flavor.
• Vitasantisa C (Vitamin C Injectable) Specific vitamin C (ascorbic acid) injectable solution at 100 mg/mL concentration, presented in 5 mL amber ampoules, 100 units per box, for deficiency treatment.
• Paracetamol Oral Drops Notified analgesic and antipyretic medication at 200 mg/mL concentration presented as oral drops in 15 mL plastic container for pediatric and adult pain/fever management.
• Rinosantisa (Sodium Chloride Nasal Spray) Notified sodium chloride nasal spray at 9 mg/mL concentration in 50 mL plastic spray bottle for nasal congestion relief.
• Contract Manufacturing Services (CMO/CDMO) Full-cycle contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services for injectable pharmaceutical products with validated facilities, specialized teams, and complete regulatory compliance and traceability. Targeted at other pharmaceutical companies seeking injectable manufacturing capacity, cost reduction, economies of scale, or more agile production processes.
• R&D Services for Injectable Pharmaceuticals Research and development services including pre-formulation, drug master file (DMF), analytical and stability development, microbiological development, pharmaceutical technology development, packaging development, and technical documentation, focused on injectable medication development. Targeted at other pharmaceutical companies and internal pipeline expansion.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• SicrediminorStrategic or Co-development PartnerSicredi partnered with Santisa for a financial education lecture during SIPAT (Semana Interna de Prevenção de Acidentes do Trabalho), providing employees with guidance on financial balance and well-being. This partnership reflects Santisa's commitment to employee welfare beyond occupational safety.
• Mary Kay (Amigas do Peito)minorStrategic or Co-development PartnerMary Kay partnered with Santisa for a breast cancer prevention awareness session (October Pink Month) during SIPAT. The partnership focused on self-care and early detection education for Santisa's workforce.
• Brazilian Public Health System (SUS) and Government EntitiescoreStrategic or Co-development PartnerSantisa participates in government health programs including Parcerias para o Desenvolvimento de Produtos (PDPs — Product Development Partnerships) and PDIL (Innovation Local), public tenders, and government procurement for essential medicines. The company identifies public health demands and offers solutions through these mechanisms.
• Other Pharmaceutical Companies (Licensing Partners)coreStrategic or Co-development PartnerSantisa's New Business area actively pursues licensing in (acquiring rights to products/technologies) and licensing out (granting rights to its products/intellectual property) arrangements. The company seeks to expand portfolios, access new products, technologies, and enter new markets through strategic alliances with other pharmaceutical companies.
• Pharmaceutical Companies (Contract Manufacturing Clients)coreImplementation/ SI/ Consulting PartnerSantisa offers CMO/CDMO contract manufacturing services to other pharmaceutical companies seeking production capacity, cost reduction, economies of scale, or more agile and flexible manufacturing processes for injectable product lines. Services include full-cycle development and production.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• EMS Pharma: Brazil's largest pharmaceutical company and a leading generics manufacturer. EMS is a direct peer given overlapping generic/similar injectable and oral product portfolios and a national distribution footprint across Brazil.
• Eurofarma Laboratórios: One of Brazil's largest pharmaceutical companies with a broad generics, similars, and branded portfolio plus CMO/CDMO services. Directly comparable to Santisa across branded generics manufacturing, injectable capability, and national distribution.
• Biolab Farmacêutica: Brazilian pharmaceutical company producing branded, generic, and hospital products. Biolab is a relevant peer to Santisa given overlapping therapeutic categories, hospital-channel focus, and Brazilian national distribution model.
• Aché Laboratórios: Major Brazilian pharmaceutical manufacturer with generics, similars, and branded prescription products. Aché competes with Santisa across generic and similar therapeutic categories and shares the national retail and hospital channel footprint.
• Cristália Produtos Químicos Farmacêuticos: Brazilian pharmaceutical company specializing in injectable and hospital products, including anesthetics, analgesics, and critical-care medications. Cristália is one of the closest direct peers to Santisa given its injectable manufacturing focus and ANVISA-regulated production base.
• Laboratório Teuto Brasileiro: Large Brazilian generics manufacturer producing oral solids, injectables, and similars with national distribution. Teuto is a direct competitor to Santisa across generic injectable and oral categories in both retail pharmacy and SUS channels.
• Medley (Sanofi): Brazilian generics manufacturer owned by Sanofi, producing a wide range of generic oral and injectable products distributed nationally. Medley competes head-to-head with Santisa in generic injectable categories such as analgesics and benzodiazepines.
• Prati-Donaduzzi: Brazilian pharmaceutical manufacturer with one of the broadest generic portfolios in the country, including injectables. Prati-Donaduzzi is a relevant peer to Santisa given shared generics/similars focus, injectable manufacturing capability, and heavy SUS tender participation.
• Libbs Farmacêutica: Brazilian pharmaceutical manufacturer producing branded generics, similars, and specialty products with national distribution. Libbs overlaps with Santisa in generic injectable categories and operates with comparable ANVISA-validated manufacturing infrastructure.
• Hipolabor Farmacêutica: Brazilian generics and injectables manufacturer supplying hospitals and the SUS. Hipolabor is a comparable peer given its similar product mix (generic injectable and hospital products) and reliance on public tenders, similar to Santisa.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/santisalab

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santisa